Systematic review with meta-analysis: The efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 7, 2015, Pages 613-623

  Gisbert, J P ^a,b   Marin A C ^a,b   McNicholl, A G ^a,b   Chaparro, M ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; ILEITIS; INFECTION; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84926162527     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13083     Document Type: Review

References (76)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al,. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
5. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE,. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
6. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
7. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
8. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
9. Yanai H, Lichtenstein L, Assa A, et al,. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2014; doi: 10.1016/j.cgh.2014.07.029. [Epub ahead of print]
10. Colombel JF, Schwartz DA, Sandborn WJ, et al,. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
11. Schreiber S, Rutgeerts P, Fedorak RN, et al,. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
12. Triantafillidis JK, Mantzaris G, Karagiannis J, et al,. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi 2010; 114: 85-90.
13. Brandse JF, Peters CP, Gecse KB, et al,. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease. Inflamm Bowel Dis 2014; 20: 251-8.
14. Ma C, Huang V, Fedorak DK, et al,. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. J Crohns Colitis 2014; 8: 1454-63.
15. Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M,. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center. Eur J Gastroenterol Hepatol 2014; 26: 458-65.
16. Peters CP, Eshuis EJ, Toxopeus FM, et al,. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis 2014; 8: 866-75.
17. Hiroz P, Vavricka SR, Fournier N, et al,. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scand J Gastroenterol 2014; 49: 1207-18.
18. Afif W, Leighton JA, Hanauer SB, et al,. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302-7.
19. Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, et al,. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24: 756-8.
20. Barthel HR, Gille T, Halbsguth A, Kramer M,. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 2005; 20: 1464-5.
21. Chaparro M, Andreu M, Barreiro-de Acosta M, et al,. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18: 5219-24.
22. Cordero Ruiz P, Castro Marquez C, Mendez Rufian V, et al,. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig 2011; 103: 294-8.
23. Danese S, Mocciaro F, Guidi L, et al,. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm Bowel Dis 2008; 14: 1168-70.
24. Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A,. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis 2010; 4: 654-60.
25. Fortea-Ormaechea JI, Gonzalez-Lama Y, Casis B, et al,. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. Gastroenterol Hepatol 2011; 34: 443-8.
26. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al,. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013; 7: 717-22.
27. Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A,. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. Dig Dis Sci 2011; 56: 3386-8.
28. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ,. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 32: 384-93.
29. Hinojosa J, Gomollon F, Garcia S, et al,. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409-18.
30. Ho GT, Smith L, Aitken S, et al,. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-15.
31. Ho GT, Mowat A, Potts L, et al,. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009; 29: 527-34.
32. Karmiris K, Paintaud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
33. Kiss LS, Szamosi T, Molnar T, et al,. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-22.
34. Lichtiger S, Binion DG, Wolf DC, et al,. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010; 32: 1228-39.
35. Lopez Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Diaz-Rubio M,. [Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study]. Rev Esp Enferm Dig 2008; 100: 676-81.
36. Lofberg R, Louis EV, Reinisch W, et al,. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18: 1-9.
37. Nichita C, Stelle M, Vavricka S, et al,. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion 2010; 81: 78-85.
38. Oussalah A, Babouri A, Chevaux JB, et al,. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416-23.
39. Oussalah A, Laclotte C, Chevaux JB, et al,. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28: 966-72.
40. Panaccione R, Loftus EV Jr, Binion D, et al,. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011; 25: 419-25.
41. Papadakis KA, Shaye OA, Vasiliauskas EA, et al,. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75-9.
42. Pariente B, Pineton de Chambrun G, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
43. Peyrin-Biroulet L, Laclotte C, Bigard MA,. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25: 675-80.
44. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA,. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328-32.
45. Sandborn WJ, Hanauer S, Loftus EV Jr, et al,. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-9.
46. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
47. Sandborn WJ, Feagan BG, Stoinov S, et al,. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
48. Sandborn WJ, Abreu MT, D'Haens G, et al,. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688-95 e2.
49. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65; e1-3.
50. Seiderer J, Brand S, Dambacher J, et al,. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 787-96.
51. Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC,. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: a single centre experience. J Crohns Colitis 2011; 5: 324-31.
52. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS,. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol 2004; 16: 627-30.
53. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT,. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther 2009; 29: 273-8.
54. Swoger JM, Loftus EV Jr, Tremaine WJ, et al,. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010; 16: 1912-21.
55. Taxonera C, Estelles J, Fernandez-Blanco I, et al,. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011; 33: 340-8.
56. Trinder MW, Lawrance IC,. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009; 24: 1252-7.
57. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ,. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
58. Youdim A, Vasiliauskas EA, Targan SR, et al,. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 333-8.
59. Armuzzi A, Biancone L, Daperno M, et al,. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis 2013; 45: 738-43.
60. Baert F, Vande Casteele N, Tops S, et al,. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther 2014; 40: 1324-32.
61. Cozijnsen M, Duif V, Kokke F, et al,. Adalimumab therapy in children with Crohn's disease previously treated with infliximab; a Dutch Nationwide Cohort Study. J Pediatr Gastroenterol Nutr 2014; [Epub ahead of print]
62. Kotze PG, Abou-Rejaile VR, Uiema LA, et al,. Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. Arq Gastroenterol 2014; 51: 39-45.
63. Matsuoka K, Kanai T,. Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-alpha monoclonal antibody treatment for Crohn's disease. Digestion 2013; 88: 17-9.
64. Dassopoulos T,. When the love is lost: adalimumab for patients with an attenuated response to infliximab. Inflamm Bowel Dis 2005; 11: 948-9.
65. Louis E, Lofberg R, Reinisch W, et al,. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis 2013; 7: 34-43.
66. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
67. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
68. Billioud V, Sandborn WJ, Peyrin-Biroulet L,. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84.
69. Danese S, Fiorino G, Reinisch W,. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
70. Patil SA, Rustgi A, Langenberg P, Cross RK,. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013; 58: 209-15.
71. Feagan BG, Sandborn WJ, Wolf DC, et al,. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011; 33: 541-50.
72. Shao LM, Chen MY, Cai JT,. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009; 29: 605-14.
73. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG,. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009; 30: 977-86.
74. Da W, Zhu J, Wang L, Lu Y,. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review. Eur J Gastroenterol Hepatol 2013; 25: 885-91.
75. Reinisch W,. How to manage loss of response to anti-TNF in Crohn's disease? Curr Drug Targets 2010; 11: 152-5.
76. Scrivo R, Conti F, Spinelli FR, et al,. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009; 61: 107-17.